Sodium butyrate is the sodium salt of butyric acid, a short-chain fatty acid related to microbial fiber fermentation in the gut and studied in humans for gastrointestinal outcomes, metabolic markers, inflammation-related endpoints, and functional-aging measures. (FDA) (Review)
Human anti-aging evidence for sodium butyrate is indirect and functional, not lifespan-based. Trials in older men and postmenopausal women have examined handgrip strength, gait speed, physical performance, postural balance, and intestinal-leak markers, while direct claims about human lifespan extension, biological-age reversal, or epigenetic-age reduction are not established by the available human trials. (Research) (Research) The broader evidence base is strongest in digestive and gastrointestinal health, mixed in inflammatory bowel disease and cardiovascular research, emerging in metabolic and joint-health studies, and mainly preclinical for direct longevity or cellular-senescence claims. (Research) (Research) (Research)
Ingredient Identity
- Official name(s): Sodium butyrate; butyric acid sodium salt. (FDA)
- Synonyms: Sodium butanoate; sodium butyrate USP; butyric acid sodium salt. (FDA)
- Classification: Short-chain fatty acid salt; FDA substance records identify sodium butyrate as a substance record under UNII 8RAS91C36W. (FDA)
- CAS number: 156-54-7 is commonly associated with sodium butyrate in chemical substance records. (FDA)
- Endogenous vs exogenous: Butyrate is produced in the colon by gut microbial fermentation of nondigestible carbohydrates, while sodium butyrate is an administered salt form used in research and supplement-style formulations. (Review)
Ingredient Snapshot
- Classification: Sodium butyrate is a short-chain fatty acid salt related to butyrate, one of the main short-chain fatty acids produced by gut microbial fermentation. (Review)
- Endogenous vs exogenous status: Butyrate is produced endogenously in the colon, while sodium butyrate is an exogenous salt form studied through oral, microencapsulated, sustained-release, controlled-release, rectal, and clinical-pharmacology formats. (Review) (Research)
- Primary human research domains: Human studies have examined sodium butyrate in digestive and gastrointestinal health, inflammatory bowel disease, diabetes and glycemic control, obesity and weight regulation, cardiovascular health, joint health, infection, cancer-research pharmacology, and aging-related physical-function outcomes. (Research) (Research)
- Common study formats: The evidence includes randomized controlled trials, pilot trials, prospective symptom studies, formulation studies, rectal-enema trials, and clinical pharmacology studies. (Research) (Research)
- Pharmacokinetic characterization status: Human evidence indicates that route and formulation strongly affect where butyrate is released and whether systemic concentrations rise meaningfully. (Research) (Research)
- Regulatory context: FDA substance records identify sodium butyrate as a substance, and FDA food-substance records list butyric acid under food-use technical-effect categories; neither source authorizes anti-aging or disease-treatment claims for sodium butyrate. (FDA) (FDA)
- Evidence maturity: Evidence is most developed for selected digestive-health outcomes, emerging for metabolic, joint-health, and functional-aging outcomes, and mainly preclinical for direct anti-aging, lifespan, or senescence claims. (Research) (Research) (Research)
Introduction
Sodium butyrate is a salt form of butyrate, a four-carbon short-chain fatty acid produced when gut bacteria ferment nondigestible carbohydrates in the large intestine. (Review) Butyrate is biologically important because colon cells can use it as an energy source, and because it participates in gut-barrier, immune, metabolic, and gene-expression signaling. (Review)
Interest in sodium butyrate often comes from its overlap with gut health, inflammation, metabolic function, and aging-related biology. (Review) Human studies have examined sodium butyrate most directly in gastrointestinal disorders, while newer trials have explored physical function in older or postmenopausal populations, metabolic outcomes, joint-health outcomes, and blood-pressure responses. (Research) (Research) (Research)
This article is informational only, describes sodium butyrate as a biochemical substance studied in human research, and does not provide medical or dosing advice. (FDA)
Quick Summary
- Sodium butyrate is the sodium salt of butyrate, a short-chain fatty acid linked to gut microbial fermentation and studied in humans using oral, microencapsulated, controlled-release, sustained-release, rectal, and clinical-pharmacology formats. (FDA) (Research)
- The strongest human anti-aging-relevant evidence is functional-aging evidence, because trials in older men and postmenopausal women reported changes in handgrip strength, gait speed, postural balance, physical performance, and intestinal-leak markers rather than lifespan or biological-age endpoints. (Research) (Research)
- Digestive and gastrointestinal health has the broadest human research base, including IBS trials, IBD trials, healthy-colon studies, and colonic-delivery research. (Research) (Research)
- IBS studies report improvement in selected symptom outcomes, while IBD findings differ across adult ulcerative-colitis trials, pediatric IBD trials, and rectal-enema reviews. (Research) (Research) (Review)
- Metabolic evidence is emerging because trials in obesity, overweight/obesity with or without type 2 diabetes, and type 2 diabetes with IBS-like symptoms used different populations, doses, and diet contexts. (Research) (Research) (Research)
- Cardiovascular evidence is cautionary because one randomized trial in mild hypertension reported increased daytime systolic and diastolic blood pressure after oral sodium butyrate. (Research)
- Direct anti-aging claims remain unsupported in humans because lifespan, senescence, mitochondrial, and Alzheimer’s-model findings are mainly animal, fly, or cell-culture evidence. (Research) (Research) (Research)
Human Research Findings by Condition
Aging and Longevity Research
Human aging-related research on sodium butyrate is best described as functional-aging research, not direct longevity research. Randomized trials have measured muscle strength, gait speed, postural balance, physical performance, and intestinal-leak markers in older or postmenopausal adults, but they have not tested lifespan extension, mortality, biological-age clocks, or telomere-length outcomes. (Research) (Research)
Key human study
Dose studied: 300 mg/day oral butyrate
Population: Older men
Duration: 16 weeks
Researchers studied oral butyrate in older men and measured postural balance, handgrip strength, gait speed, zonulin, lipopolysaccharide-binding protein, CRP, and 8-isoprostane. (Research) The trial reported improvements in handgrip strength, gait speed, and postural-balance measures, with reductions in intestinal-leak markers but no clear effect on CRP or 8-isoprostane. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 570 mg/day sodium butyrate
Population: Postmenopausal women
Duration: 12 weeks
A randomized controlled trial in postmenopausal women studied sodium butyrate and measured handgrip strength, gait speed, short physical performance battery, zonulin, and lipopolysaccharide-binding protein. (Research) The study reported improved handgrip strength and physical performance, making it relevant to functional-aging research but not to direct lifespan or biological-age claims. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Emerging
Study source: (Research)
Preclinical context
Sodium butyrate has been studied in Drosophila longevity experiments, D-galactose rat aging models, Alzheimer’s mouse models, and cellular-senescence models. (Research) (Research) (Research) These studies support biological plausibility for aging research, but they are not human evidence that sodium butyrate slows aging or extends lifespan. (Research)
Digestive and Gastrointestinal Health
Digestive and gastrointestinal health is the most developed human research area for sodium butyrate. Human studies have examined IBS symptoms, inflammatory bowel disease, colonic oxidative-stress markers, colonic gene expression, rectal delivery, and controlled-release intestinal delivery. (Research) (Research) (Research)
Key human study
Dose studied: 300 mg/day microencapsulated sodium butyrate
Population: Adults with irritable bowel syndrome
Duration: 12 weeks
A randomized placebo-controlled trial studied microencapsulated sodium butyrate in adults with IBS and reported reduced frequency of selected symptoms, including abdominal pain during defecation, urgency, and bowel-habit disturbance. (Research) The study did not show uniform improvement across every symptom category, so the evidence should be described as symptom-specific rather than broadly curative. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 150 mg twice daily microencapsulated sodium butyrate
Population: 3,000 non-hospitalized adults with IBS
Duration: 12 weeks
A prospective multicenter study observed adults with confirmed IBS treated with sodium butyrate in a triglyceride matrix at 150 mg twice daily for 12 weeks. (Research) The study reported symptom reductions, but the lack of placebo control limits how strongly the findings can be attributed to sodium butyrate. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Inflammatory Bowel Disease
Inflammatory bowel disease evidence is mixed and formulation-dependent. Adult ulcerative-colitis studies include add-on microencapsulated sodium butyrate and older mesalazine-combination studies, while pediatric IBD and rectal-enema evidence have produced less consistent results. (Research) (Research) (Review)
Key human study
Dose studied: 300 mg twice daily microencapsulated sodium butyrate
Population: Adults with active mild-to-moderate ulcerative colitis
Duration: 8 weeks
A multicenter double-blind randomized placebo-controlled trial studied microencapsulated sodium butyrate as add-on therapy in 98 adults with mild-to-moderate ulcerative colitis. (Research) The study reported remission-related benefit in this adult ulcerative-colitis context, but the result should not be generalized to all IBD populations or to sodium butyrate monotherapy. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)
Additional human study
Dose studied: 150 mg sodium butyrate twice daily
Population: Children and adolescents aged 6–18 with colonic Crohn’s disease or ulcerative colitis
Duration: 12 weeks
A randomized placebo-controlled multicenter trial studied sodium butyrate as adjunctive therapy in pediatric inflammatory bowel disease. (Research) The trial did not show clear efficacy on disease activity or remission, which makes the IBD evidence mixed across populations. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Mixed
Study source: (Research)
Diabetes and Glycemic Control
Human diabetes-related evidence is emerging and overlaps with gastrointestinal symptom research. Sodium butyrate has been studied in people with type 2 diabetes and IBS-like symptoms, and in mixed overweight/obesity populations with or without type 2 diabetes. (Research) (Research)
Key human study
Dose studied: 1.5 g/day microencapsulated sodium butyrate
Population: Adults with type 2 diabetes meeting Rome IV criteria for IBS
Duration: 12 weeks
A randomized placebo-controlled trial studied microencapsulated sodium butyrate in people with type 2 diabetes and IBS-like symptoms. (Research) The study reported improvement in gastrointestinal symptoms and examined carbohydrate-metabolism outcomes, but the population combines metabolic disease with a gastrointestinal symptom phenotype. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 1,875 mg/day oral sodium butyrate with a moderately hypoenergetic diet
Population: Adults aged 30–70 with overweight or obesity, with or without type 2 diabetes
Duration: 12 weeks
A proof-of-concept randomized controlled trial evaluated whether oral sodium butyrate improved body weight and metabolic profile when combined with a moderately hypoenergetic diet. (Research) The study is useful for metabolic research context, but its diet co-intervention limits attribution to sodium butyrate alone. (Research)
Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)
Obesity and Weight Regulation
Human obesity research is preliminary and mainly focused on short-term metabolic markers, gene-expression outcomes, and diet-supported interventions. Current trials do not establish sodium butyrate as an obesity treatment. (Research) (Research)
Key human study
Dose studied: 600 mg/day sodium butyrate with a hypocaloric diet
Population: Adults with obesity
Duration: 8 weeks
A triple-blind randomized placebo-controlled trial studied PGC-1α, PPAR-α, UCP1 gene expression, metabolic markers, and anthropometric measures in adults with obesity. (Research) The trial reported increases in PGC-1α and UCP1 expression, while broader anthropometric and biochemical findings were limited. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 1,875 mg/day oral sodium butyrate with a moderately hypoenergetic diet
Population: Adults with overweight or obesity, with or without type 2 diabetes
Duration: 12 weeks
A proof-of-concept randomized controlled trial studied sodium butyrate with a calorie-reduced diet and assessed body weight and metabolic profile. (Research) The study provides human dose and exposure context, but the diet co-intervention means the findings cannot be interpreted as sodium butyrate alone. (Research)
Result: Human clinical studies reported mixed findings
Evidence strength: Emerging
Study source: (Research)
Cardiovascular Health
Cardiovascular evidence is cautionary rather than clearly supportive. A randomized trial in mild hypertension reported increased daytime systolic and diastolic blood pressure after oral sodium butyrate supplementation. (Research)
Key human study
Dose studied: 3.9 g/day oral sodium butyrate
Population: Adults with mild hypertension
Duration: 4 weeks
A randomized placebo-controlled trial studied oral sodium butyrate in adults with mild hypertension after antihypertensive medication discontinuation and washout. (Research) The study reported increased daytime systolic and diastolic blood pressure in the sodium-butyrate group compared with placebo. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Moderate for lack of benefit in this context
Study source: (Research)
Joint Health
Human joint-health research has examined butyrate in knee osteoarthritis and sustained-release butyrate in hand osteoarthritis. The evidence is early and mainly connects physical function, lipopolysaccharide-binding protein, and immune-cell activation markers. (Research) (Research)
Key human study
Dose studied: 300 mg/day butyrate
Population: Adults with knee osteoarthritis
Duration: 12 weeks
A double-blind study in knee osteoarthritis reported that butyrate improved physical-function measures and reduced lipopolysaccharide-binding protein-related markers. (Research) The findings are relevant to mobility and inflammation-linked function, but they do not establish effects on structural joint repair. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: 600 mg/day sustained-release butyrate
Population: Adults with hand osteoarthritis
Duration: 4–5 weeks
A double-blind placebo-controlled randomized trial studied sustained-release butyrate tablets in hand osteoarthritis and measured serum inflammatory markers and ex vivo T-helper-cell activation. (Research) The trial did not change serum inflammatory markers but reduced selected ex vivo T-helper-cell activation measures, making the finding mechanistic and exploratory. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Study source: (Research)
Infection
Human infection research is limited and disease-specific. Sodium butyrate has been studied as a rectal adjunct in shigellosis, with outcomes focused on mucosal inflammation, endoscopic and histologic findings, LL-37 expression, and stool cytokines. (Research)
Key human study
Dose studied: 80 mM sodium butyrate enemas twice daily
Population: Adults with shigellosis
Duration: 3 days
A randomized double-blind placebo-controlled trial studied sodium-butyrate enemas in adults with shigellosis. (Research) The study reported early reductions in inflammatory markers and enhanced LL-37-related mucosal responses, but no obvious effect on clinical recovery from shigellosis. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Study source: (Research)
Cancer Research
Cancer-related human evidence for sodium butyrate is primarily historical clinical pharmacology rather than modern efficacy evidence. Early work in acute leukemia found low plasma sodium-butyrate concentrations and short in vivo half-life, which helps explain limited systemic pharmacologic effects. (Research)
Key human study
Dose studied: Clinical pharmacology dosing in acute leukemia
Population: People with acute leukemia
Duration: Short-term clinical pharmacology context
A clinical pharmacology study evaluated sodium butyrate in people with acute leukemia and reported that plasma concentrations reached only 39–59 μM during infusion. (Research) The authors stated that apparent lack of clinical efficacy may have been explained by low plasma levels due to short in vivo half-life. (Research)
Result: Human clinical study reported no clear effect
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human sodium-butyrate studies use several exposure formats: oral milligram dosing, microencapsulated oral dosing, sustained-release tablets, controlled-release gut-targeted formulations, rectal enemas measured in millimolar concentrations, and clinical-pharmacology systemic exposure. (Research) (Research) Oral milligram doses and rectal millimolar enemas should not be treated as equivalent because they expose different tissues and produce different systemic kinetics. (Research)
300 mg/day oral or microencapsulated sodium butyrate:
This is one of the lowest repeated oral exposure ranges in the reviewed human evidence and appears in IBS, pediatric IBD, older-adult physical-function, and combination-formulation research. (Research) In IBS, 300 mg/day microencapsulated sodium butyrate for 12 weeks reduced selected symptom frequencies rather than uniformly improving all symptom outcomes. (Research) In older men, 300 mg/day oral butyrate for 16 weeks improved handgrip strength, gait speed, and postural-balance measures. (Research) In pediatric IBD, 150 mg twice daily did not show clear efficacy on disease activity or remission. (Research)
Result: Mixed findings
Evidence strength: Moderate for selected IBS outcomes; emerging for functional aging; mixed for pediatric IBD
Notes / limitations: Similar daily doses produced different findings across different populations and conditions.
570–600 mg/day sodium butyrate or sustained-release butyrate:
This exposure range includes postmenopausal functional-aging research, obesity research, hand osteoarthritis research, and adult ulcerative-colitis add-on research. (Research) (Research) The postmenopausal trial used 570 mg/day for 12 weeks and reported improved handgrip strength and physical performance. (Research) The obesity trial used 600 mg/day with a hypocaloric diet and reported changes in PGC-1α and UCP1 gene-expression markers. (Research) The adult ulcerative-colitis trial used 300 mg twice daily as add-on therapy for 8 weeks. (Research)
Result: Preliminary signal
Evidence strength: Emerging to moderate, depending on condition
Notes / limitations: The same total daily range appears across very different conditions and formulations.
1.5–1.875 g/day oral or microencapsulated sodium butyrate:
Higher oral sodium-butyrate exposures have been studied in metabolic and gastrointestinal-symptom contexts. (Research) A 1.5 g/day microencapsulated sodium-butyrate trial in type 2 diabetes patients with IBS-like symptoms reported improvements in gastrointestinal symptoms and examined carbohydrate-metabolism outcomes. (Research) A 1,875 mg/day proof-of-concept trial studied overweight or obese adults with or without type 2 diabetes while both groups followed a moderately hypoenergetic diet. (Research) These studies are useful for metabolic research context but do not establish sodium butyrate as a weight-loss or diabetes therapy. (Research)
Result: Mixed findings
Evidence strength: Emerging
Notes / limitations: Diet co-interventions and mixed populations limit attribution to sodium butyrate alone.
1.8 g/day microencapsulated sodium butyrate:
A placebo-controlled pilot study in IBD used 1,800 mg/day microencapsulated sodium butyrate for two months as add-on therapy. (Research) The study focused on microbiota-related outcomes in Crohn’s disease and ulcerative colitis rather than direct symptom cure or anti-aging endpoints. (Research) This exposure level shows that some IBD research uses substantially higher oral doses than those used in many IBS and functional-aging studies. (Research)
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Pilot-study size and add-on design limit interpretation.
3.9 g/day oral sodium butyrate:
A hypertension trial used 3.9 g/day oral sodium butyrate for four weeks. (Research) The study reported increased daytime systolic and diastolic blood pressure compared with placebo. (Research) This finding is important because it shows that higher oral sodium-butyrate exposure should not be assumed to have favorable cardiovascular effects. (Research)
Result: Neutral overall findings
Evidence strength: Moderate for the studied hypertension context
Notes / limitations: This was a hypertension-specific trial after medication washout and should not be generalized to all users or outcomes.
80–100 mM rectal sodium butyrate enemas:
Rectal studies have used 80 mM sodium-butyrate enemas in shigellosis and 100 mM sodium-butyrate enemas in healthy-colon oxidative-stress and gene-expression studies. (Research) (Research) In healthy volunteers, 100 mM rectal butyrate altered glutathione-related oxidative-stress measures and colonic mucosal gene-expression patterns. (Research) (Research) Rectal pharmacokinetic research found that hepatic uptake prevents a large systemic increase in butyrate concentrations after rectal administration. (Research)
Result: Human studies observed short-term physiological effects
Evidence strength: Limited to local colonic and acute-disease contexts
Notes / limitations: Rectal millimolar exposure is not directly comparable to oral supplement-style milligram dosing.
Key Takeaways from Human Research
- Sodium butyrate’s anti-aging evidence in humans is best framed as functional-aging research, because studies measured strength, gait, physical performance, balance, and intestinal-leak markers rather than lifespan or biological-age outcomes. (Research) (Research)
- Digestive and gastrointestinal health has the broadest human evidence base, especially IBS symptom research, ulcerative-colitis add-on trials, IBD pilot studies, and colonic-delivery research. (Research) (Research) (Research)
- IBD evidence is mixed because adult ulcerative-colitis studies, pediatric IBD studies, and rectal-enema evidence do not all point in the same direction. (Research) (Review)
- Metabolic studies are early and often include diet co-interventions, which limits conclusions about sodium butyrate alone. (Research) (Research)
- Cardiovascular research includes a randomized hypertension trial with unfavorable blood-pressure findings, so cardiovascular benefits should not be inferred from animal or mechanistic studies. (Research)
- Preclinical aging studies support biological plausibility but do not establish human anti-aging efficacy. (Research) (Research)
Origin & Natural Occurrence
Butyrate is naturally produced in the colon when gut microbes ferment nondigestible carbohydrates such as dietary fiber and resistant starch. (Review) This endogenous butyrate production is different from taking sodium butyrate as an administered salt form. (FDA)
Butyric acid is listed in FDA’s Substances Added to Food database for food-use technical effects such as antioxidant, flavoring agent or adjuvant, and pH-control agent. (FDA) That FDA food-substance entry refers to butyric acid and does not authorize sodium-butyrate anti-aging or disease-treatment claims. (FDA)
Manufactured sodium butyrate used in studies may be delivered as oral capsules, microencapsulated formulations, sustained-release tablets, controlled-release intestinal formulations, rectal enemas, or clinical-pharmacology infusions. (Research) (Research) (Research)
How It Behaves in the Body
In plain language, butyrate acts as both a fuel and a signal. Colon cells can metabolize butyrate for energy, while other effects involve gut-barrier biology, immune signaling, metabolism, and gene regulation. (Review)
One important mechanism is histone deacetylase inhibition, which means butyrate can influence how DNA-associated proteins are packaged and how some genes are expressed. (Review) This mechanism helps explain why sodium butyrate appears in aging, inflammation, cancer-biology, and senescence research, but a mechanism alone does not prove clinical benefit. (Research) (Research)
Butyrate also acts through short-chain-fatty-acid receptor biology, including receptors commonly discussed as FFAR2/GPR43 and FFAR3/GPR41. (Review) These receptor pathways connect microbial metabolites to immune and metabolic signaling, but human clinical outcomes depend on route, formulation, exposure, and population. (Research) (Research)
What is well established is that butyrate is a biologically active short-chain fatty acid involved in colonic metabolism and signaling. (Review) What remains less established is whether supplemental sodium butyrate reliably produces systemic anti-aging effects in humans. (Research) (Review)
Absorption & Delivery Formats
Oral immediate-release: Oral sodium butyrate has been used in capsule-style human trials, including hypertension and metabolic studies. (Research) Oral sodium butyrate increased circulating butyrate in the hypertension trial, but the trial reported increased daytime blood pressure rather than benefit. (Research)
Oral microencapsulated: Microencapsulated sodium butyrate has been used in IBS, IBD, and type 2 diabetes with IBS-like symptoms. (Research) Microencapsulation is used to alter delivery and intestinal release, which matters because local colonic exposure may differ from systemic exposure. (Review)
Oral sustained-release: Sustained-release butyrate has been studied in hand osteoarthritis, where researchers measured systemic inflammatory markers and ex vivo T-helper-cell activation. (Research) This format is relevant when researchers are trying to extend intestinal exposure rather than deliver a rapidly absorbed dose. (Research)
Oral controlled-release: Controlled-release sodium-butyrate formulations have been studied for ileo-cecal and colonic release in healthy subjects and Crohn’s disease patients. (Research) This evidence supports the point that formulation can materially change where sodium butyrate becomes available in the gut. (Research)
Sublingual: The verified human evidence set used for this article did not identify sublingual sodium-butyrate studies. (Review)
Transdermal: The verified human evidence set used for this article did not identify transdermal sodium-butyrate studies. (Review)
Injectable / IV: Early clinical pharmacology in acute leukemia evaluated systemic sodium-butyrate exposure and reported low plasma levels and short in vivo half-life. (Research) This route belongs to clinical-pharmacology research and should not be treated as a supplement delivery format. (Research)
Quick Facts at a Glance
Onset (reported)
Reported study timelines vary by route and condition. Rectal shigellosis research measured outcomes over three days, while many oral IBS, IBD, metabolic, and functional-aging studies measured outcomes over 8–16 weeks. (Research) (Research)
Time to peak (Tmax)
A single standardized Tmax for oral sodium butyrate is not established across the human evidence because formulations differ. Controlled-release research shows that delivery can be shifted toward the ileo-cecal region and colon, so release timing depends on formulation technology. (Research)
Half-life (t½)
Clinical pharmacology work reported that sodium butyrate had a short in vivo half-life in systemic-exposure research. This short half-life helps explain why maintaining systemic pharmacologic concentrations may be difficult with some exposure routes. (Research)
Typical duration
Human study durations in this evidence set range from three days in rectal shigellosis research to 16 weeks in older-adult physical-function research. Most oral IBS, IBD, and metabolic trials assessed outcomes over 8–12 weeks. (Research) (Research) (Research)
Absorption routes studied
Human research has studied oral, microencapsulated oral, sustained-release oral, controlled-release oral, rectal, and systemic clinical-pharmacology exposure. Rectal pharmacokinetic work suggests substantial local colonic exposure with hepatic uptake limiting large systemic increases. (Research) (Research)
Formulation differences
Formulation is one of the most important interpretation issues for sodium butyrate. Microencapsulated, sustained-release, and controlled-release products may differ in release site, local intestinal exposure, tolerability, and systemic exposure. (Research) (Review)
Variability drivers
Population, diagnosis, route, dose, delivery technology, background diet, and co-interventions all affect study interpretation. For example, obesity trials often include hypocaloric diets, while IBS trials may use microencapsulated or combination formulations. (Research) (Research)
Tolerance / adaptation
The verified human evidence does not establish a clear tolerance or adaptation pattern for sodium butyrate. Some studies report short-term tolerability, but tolerability over weeks is not the same as demonstrating long-term adaptation or absence of tolerance. (Research) (Review)
Evidence strength snapshot
Evidence is most developed for digestive and gastrointestinal research, especially IBS symptom outcomes, IBD add-on studies, and colonic-delivery research. Evidence is emerging for functional-aging, metabolic, and joint-health outcomes, while direct anti-aging claims remain mainly preclinical. (Research) (Research) (Research)
Other Physiological Contexts Studied (If Applicable)
- Healthy human colonic mucosa studies found that rectal butyrate changed glutathione-related oxidative-stress measures and gene-expression patterns related to fatty-acid metabolism, electron transport, and oxidative stress. (Research) (Research)
- Human longevity microbiome research has associated long-lived populations with SCFA- or butyrate-related microbial functions, but these observational studies do not test sodium-butyrate supplementation. (Review) (Research)
- Alzheimer’s mouse-model studies reported sodium-butyrate effects on memory and amyloid-related outcomes, but those are preclinical neurological findings rather than human cognitive-health evidence. (Research) (Research)
- Cellular-senescence research has reported sodium-butyrate effects on D-galactose-induced senescence markers in WI-38 fibroblast models, but in vitro results cannot establish human anti-aging benefit. (Research)
- Drosophila longevity research found stage- and genotype-dependent effects of sodium butyrate, showing that preclinical longevity findings are context-dependent rather than uniformly beneficial. (Research)
Safety, Interactions & Regulation
Human safety and tolerability evidence varies by dose, population, route, formulation, and co-intervention. An IBS trial of a combination containing microencapsulated sodium butyrate, probiotics, and scFOS reported that the combination was safe and well tolerated, but that result cannot isolate sodium butyrate alone. (Research)
A pediatric IBD trial reported no adverse events in the sodium-butyrate group but also reported no clear efficacy on disease activity. (Research) A hypertension trial reported increased daytime systolic and diastolic blood pressure after 3.9 g/day oral sodium butyrate, which is a relevant caution for cardiovascular contexts. (Research)
Specific interaction evidence is not well characterized in the verified sodium-butyrate human literature. Potentially relevant research contexts include gastrointestinal therapies, antihypertensive medication contexts, glucose-regulating therapy contexts, and IBD add-on therapy, but direct interaction risks require dedicated clinical study. (Research) (Research)
Population cautions are especially relevant for people with hypertension, inflammatory bowel disease, pediatric gastrointestinal disease, pregnancy, lactation, serious chronic illness, or complex medication use because the human studies are condition-specific and not broadly generalizable. (Research) (Research)
FDA’s Substance Registration System identifies sodium butyrate as a substance record, but that identity record is not an FDA approval for anti-aging, disease-treatment, or disease-prevention claims. (FDA) FDA’s food-substance database lists butyric acid, not sodium butyrate, with food-use technical-effect categories and a 21 CFR 182.60 reference. (FDA)
FDA explains that intentionally added food substances require food-additive approval unless they are GRAS under the conditions of intended use or otherwise exempt. (FDA) EFSA describes the EU novel-food safety assessment framework, but the verified source set used for this article did not identify an EFSA-authorized anti-aging claim for sodium butyrate. (EFSA)
Evidence Overview
The overall human evidence for sodium butyrate is strongest in digestive and gastrointestinal health, emerging in metabolic and joint-health contexts, cautionary in hypertension, and indirect for aging and longevity research. Human anti-aging evidence currently centers on functional endpoints such as handgrip strength, gait speed, physical performance, postural balance, and intestinal-leak markers, not lifespan extension, biological-age clocks, telomere length, or mortality. (Research) (Research) (Research) Confidence is not higher because studies use different routes, formulations, populations, outcomes, durations, and co-interventions. (Research) (Research)
Digestive and gastrointestinal health has the broadest human research base. IBS trials report improvement in selected symptom outcomes, while prospective non-placebo IBS data support symptom signals but are more limited by design. (Research) (Research) IBD evidence is mixed because adult ulcerative-colitis add-on findings differ from pediatric IBD results and rectal-enema systematic-review evidence. (Research) (Research) (Review)
Metabolic research remains early. Obesity and overweight/obesity trials often include hypocaloric diets, which makes it difficult to isolate sodium butyrate’s independent contribution. (Research) (Research) A trial in type 2 diabetes with IBS-like symptoms reported gastrointestinal and carbohydrate-metabolism findings, but that combined phenotype limits generalization to type 2 diabetes as a whole. (Research)
Anti-aging claims require the greatest caution. Human microbiome studies associate long-lived populations or oldest-old groups with SCFA-related microbial features, but observational microbiome research cannot prove that sodium-butyrate supplementation slows aging. (Review) (Research) Animal and cell studies report effects on lifespan, memory, amyloid biology, mitochondrial stress, and senescence markers, but those findings remain preclinical. (Research) (Research) (Research)
Formulation is a central reason why results differ across studies. Rectal butyrate can create local colonic exposure, controlled-release products can shift delivery toward the ileo-cecal region and colon, and systemic exposure may be limited by rapid metabolism and hepatic uptake. (Research) (Research) Stronger conclusions would require larger, longer, independently replicated trials using standardized formulations, prespecified endpoints, and direct aging biomarkers if anti-aging claims are being evaluated. (Research) (Review)
Evidence Confidence Classification
Limited / Mixed is the best overall classification for sodium butyrate because human evidence is moderate for selected digestive-health findings, emerging for functional-aging and metabolic outcomes, mixed in IBD, cautionary in hypertension, and mainly preclinical for direct anti-aging claims. (Research) (Research) (Research)
The classification reflects multiple human studies but substantial heterogeneity in dose, formulation, delivery route, population, outcome selection, and study duration. (Research) (Research) The aging-related evidence is promising enough to justify research interest, but it is not strong enough to support claims that sodium butyrate slows human aging or extends lifespan. (Research) (Review)
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Tributyrin
- Calcium butyrate
- Magnesium butyrate
- Resistant starch
- Inulin
- Fructooligosaccharides
- Beta-glucan
- Probiotic blends
- Postbiotic preparations
- Acetate
- Propionate
- Beta-hydroxybutyrate
Medical / pharma comparator categories:
- 5-aminosalicylic acid therapies for ulcerative-colitis research context
- Antihypertensive medication categories
- Glucose-lowering medication categories
- Anti-inflammatory IBD therapies
- Symptom-directed IBS therapies
- Clinical nutrition and weight-management interventions
- Investigational histone-deacetylase-inhibitor categories
Combination Context
Sodium Butyrate + Probiotics + short-chain Fructooligosaccharides:
A randomized double-blind placebo-controlled IBS trial studied a combination of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides. (Research) The study reported symptom and tolerability findings, but the combination design means the result cannot be attributed to sodium butyrate alone. (Research)
Sodium Butyrate + Mesalazine:
Sodium butyrate has been studied with mesalazine in ulcerative-colitis research. (Research) This combination reflects an add-on gastrointestinal research context and should not be generalized to unrelated uses. (Research)
Sodium Butyrate + Hypocaloric Diet:
Sodium butyrate has been studied alongside hypocaloric or moderately hypoenergetic diets in obesity and overweight/obesity metabolic research. (Research) (Research) These studies help evaluate metabolic outcomes but cannot fully isolate sodium butyrate from the dietary intervention. (Research)
Sodium Butyrate + Standard IBD Therapy:
Pediatric IBD research studied sodium butyrate as adjunctive therapy in children and adolescents receiving standard therapy. (Research) The trial did not show clear efficacy on disease activity, so this combination context is mixed rather than clearly supportive. (Research)
FAQ
What is sodium butyrate?
Sodium butyrate is the sodium salt of butyrate, a short-chain fatty acid connected to gut microbial fermentation. (FDA) Butyrate is produced when gut microbes ferment nondigestible carbohydrates in the colon. (Review) Sodium butyrate is an administered salt form used in human and preclinical research. (FDA)
What does human research study sodium butyrate for?
Human research studies sodium butyrate mainly for digestive and gastrointestinal health, with additional studies in functional-aging outcomes, diabetes and glycemic control, obesity and weight regulation, cardiovascular health, joint health, infection, and cancer-research pharmacology. (Research) (Research) IBS and IBD studies form a large part of the clinical literature. (Research) Functional-aging studies have measured strength, gait, physical performance, balance, and intestinal-leak markers. (Research)
What are the best-supported uses?
The best-supported human research area is digestive and gastrointestinal health, especially selected IBS symptom outcomes and intestinal-delivery research. (Research) Adult ulcerative-colitis add-on evidence is positive in at least one recent trial, but IBD evidence remains mixed across populations and formats. (Research) (Research) Functional-aging evidence is promising but indirect because it does not measure lifespan or biological age. (Research)
Where is evidence mixed or limited?
Evidence is mixed in IBD, metabolic research, cardiovascular health, and direct anti-aging claims. (Research) (Research) Metabolic trials often include calorie-restricted diets, which limits attribution to sodium butyrate alone. (Research) Direct anti-aging evidence is limited because human studies have not established effects on lifespan, biological-age clocks, telomere length, or mortality. (Research)
How quickly does sodium butyrate act?
Reported timelines depend on the route and outcome studied. (Research) Rectal shigellosis research measured outcomes over three days. (Research) IBS, IBD, metabolic, and functional-aging studies commonly measured outcomes after 8–16 weeks. (Research) (Research)
What affects absorption and variability?
Absorption and variability depend on route, dose, release technology, gut condition, background diet, and study population. (Research) Controlled-release formulations can shift delivery toward the ileo-cecal region and colon. (Research) Rectal pharmacokinetic research suggests hepatic uptake can prevent large systemic increases after local administration. (Research)
Is tolerance reported?
The verified human evidence does not establish a clear tolerance pattern for sodium butyrate. (Review) Some trials report short-term tolerability, but tolerability is different from proving long-term adaptation or absence of tolerance. (Research) Longer standardized studies would be needed to evaluate tolerance directly. (Review)
Why do studies disagree?
Studies disagree partly because sodium butyrate is delivered in different ways, including oral capsules, microencapsulated products, sustained-release tablets, controlled-release formulations, and rectal enemas. (Research) (Research) Studies also differ by population, including IBS patients, IBD patients, older adults, postmenopausal women, hypertensive adults, and people with obesity or type 2 diabetes. (Research) (Research) Co-interventions such as hypocaloric diets or probiotic-prebiotic mixtures further limit attribution to sodium butyrate alone. (Research) (Research)
What ingredients is sodium butyrate commonly combined with and why?
Sodium butyrate has been studied with probiotics and short-chain fructooligosaccharides in IBS to evaluate combined effects on symptoms and quality of life. (Research) It has also been studied with mesalazine in ulcerative-colitis research. (Research) In metabolic research, sodium butyrate has been combined with hypocaloric diets, which makes the study context diet-plus-supplement rather than sodium butyrate alone. (Research)
What foods naturally contain sodium butyrate?
Sodium butyrate is mainly discussed in the verified evidence as an administered salt form rather than as a primary whole-food nutrient. (FDA) Butyrate itself is produced in the colon from microbial fermentation of nondigestible carbohydrates. (Review) FDA’s food-substance database lists butyric acid, not sodium butyrate, for food-use technical-effect context. (FDA)
How is sodium butyrate regulated?
FDA’s Substance Registration System identifies sodium butyrate as a substance record, but that record is not an approval for anti-aging, disease-treatment, or disease-prevention claims. (FDA) FDA’s food-substance database lists butyric acid under food-use technical-effect categories and 21 CFR 182.60 context, but that does not authorize sodium-butyrate supplement health claims. (FDA) EFSA describes the EU novel-food assessment framework, but the verified evidence set did not identify an EFSA-authorized anti-aging claim for sodium butyrate. (EFSA)
Resources
- Sodium Butyrate Substance Record — FDA GSRS — https://precision.fda.gov/ginas/app/ui/substances/8RAS91C36W
- Butyric Acid Food Substance Record — FDA — https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=BUTYRICACID&set=FoodSubstances
- Generally Recognized as Safe Framework — FDA — https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras
- Novel Food Topic Page — EFSA — https://www.efsa.europa.eu/en/topics/topic/novel-food
- Microencapsulated Sodium Butyrate in IBS — PubMed — https://pubmed.ncbi.nlm.nih.gov/22738315/
- Oral Butyrate in Older Men — PubMed — https://pubmed.ncbi.nlm.nih.gov/40577952/
- Sodium Butyrate in Postmenopausal Women — PubMed — https://pubmed.ncbi.nlm.nih.gov/40167641/
- Oral Butyrate in Hypertension — PubMed — https://pubmed.ncbi.nlm.nih.gov/39034917/
- Controlled-Release Sodium Butyrate Formulation — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC4146871/
- Rectal Butyrate Pharmacokinetics — PubMed — https://pubmed.ncbi.nlm.nih.gov/26156796/
- Gut Microbiome, Aging, and Longevity Review — PubMed — https://pubmed.ncbi.nlm.nih.gov/33297486/
- Drosophila Sodium-Butyrate Longevity Study — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC3899347/
More from the Medical & Health Conditions Encyclopedia
